secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2024-12-19T23:59:59+00:00
Accession:  0000950170-24-138446
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene reports FY2024 net loss $55.1M; cash $297.9M; LEGEND study on track for mid-2026 BLA
--------------------------------------------------------------------------------

- Net loss $55.1M ($1.46/sh) vs $104.7M in FY2023; operating expenses $62.3M up from $26.1M.
- Cash, cash equivalents and marketable securities $297.9M; expected to fund operations into 2027.
- Preliminary LEGEND pivotal data: 71% anytime CR rate in BCG-unresponsive NMIBC with CIS; BLA filing on track for mid-2026.
- First Amendment with Hercules Capital reallocates $7.5M to Tranche 3; total $50M facility unchanged.
- Appointed Joan Connolly as CTO, Anthony Cheung as CSO, Alex Nichols as Chief Strategy & Operations Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/0000950170-24-138446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000095017024138446/engn-20241219.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-138446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer